SNTA looks good heading into ASCO, what else are you buying/holding?
PPHM--final data release this quarter of 2 phase 2 trials, could be a double from here IF trial "irregularities" have been adequately addressed.
THLD-- 80% Institutionally owned, few free shares, explosive potential, big Sarcoma trial results this year-- it'll have a run-up beforehand
ZLCS-- dirt cheap, massive upside potential at current price, an all or nothing gamble in Z160 pain drug
Yes, I know the risks here with PPHM!
But, overall, I view their cancer drug in the same light as ours (Synta's) and Thresholds...
All three are first or best in class new cancer drugs with potentially broad usage for many cancer types and therefore massive potential.
I put Ganetespib's odds as the best of the three--next is Threshold's TH-302, and PPHM's drug (bavi) is at the bottm